Dorzolamide Hydrochloride Successfully Treats Open Angle Glaucoma

Dorzolamide Hydrochloride Successfully Treats Open Angle Glaucoma

Dorzolamide-HydrochlorideDorzolamide Hydrochloride is an eye drop indicated for the treatment of ocular hypertension and open angle glaucoma. Also known by the trade names Trusopt and Cosopt, Dorzolamide Hydrochloride works by inhibiting the isoenzyme carbonic anhydrase, also termed CA-II. This inhibition helps to decrease the amount of fluid made within the eye, thus decreasing pressure in the affected eye(s). Those patients who have severe kidney disease, or an allergy to sulfonamide should not take Dorzolamide Hydrochloride. Typical side effects include a bitter taste in the mouth, burning and stinging in the eye after administration, blurred vision and eye dryness. Approved by the FDA in 1994, Merck currently markets Trusopt and Cosopt.

Clinical studies tout the success of dorzolamide Hydrochloride not only for humans, but also for pets. One such study, titled “The effect of dorzolamide 2% on circadian intraocular pressure in cats with primary congenital glaucoma.”, was published in the September 16, 2011 issue of Veterinary Ophthalmology. This small, but important study involved adult cats who were given a placebo daily for five days, every eight hours, and then dorzolamide 2%, for five consecutive days, every eight hours. Fluctuations in circadian intraocular pressure, or IOP, were measured as a baseline, and then throughout the study.


Results were encouraging, showing topical dorzolamide 2% was effective at lowering the IOP in the glaucomatous cats. In addition, there were no adverse affects noted in the cats who participated, including no evidence of irritation to the treated eye areas as well. This galvanizing information is inspiring for future researchers looking for treatments for the ever growing pet population worldwide. Dogs are also excellent candidates for treatment with dorzolamide Hydrochloride  for open angle glaucoma. Breeds especially prone to this disease are the American Cocker Spaniel, the Basset Hound and the Boston Terrier. Patients, human and animal alike, are continuing to benefit from treatment with dorzolamide Hydrochloride.

Dorzolamide Hydrochloride CAS# 130693-82-2 is available for research and development purposes. LGM Pharma also supplies the Dorzolamide Hydrochloride (TEVA API) for compounding purposes in the U.S.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service